Cryo-Cell inked an R&D agreement with Saneron CCEL Therapeutics to develop regenerative therapies using Cryo-Cell’s C’elle menstrual stem cell technology. The partners will work on preclinical models for particular neurological diseases.
Cryo-Cell will provide C’elle menstrual stem cells along with associated techniques. Saneron will contribute study materials and research methodology for potential therapeutic applications. The companies will jointly own any intellectual property resulting from this research.
Cryo-Cell and Saneron will, according Julie Allickson, Ph.D., Cryo-Cell’s vp of laboratory operations and R&D, “explore utilization of C’elle menstrual stem cells in the development of potential breakthrough therapies for three very devastating disorders.”
C’elle stem cells, derived from menstrual flow, contains millions of stem cells that have many properties and characteristics similar to those of both bone marrow and embryonic stem cells, according to the firms.